Abstract
The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Current Topics in Medicinal Chemistry
Title:A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology
Volume: 12 Issue: 15
Author(s): C. Faivre, D. Barbolosi and A. Iliadis
Affiliation:
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Abstract: The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Export Options
About this article
Cite this article as:
Faivre C., Barbolosi D. and Iliadis A., A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531469
DOI https://dx.doi.org/10.2174/156802612803531469 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Biomolecular Computers
Current Bioinformatics Fork Head Transcription Factors
Current Genomics Genetic Polymorphisms and Haplotypes of Major Drug Metabolizing Enzymes in East Asians and Their Comparison with Other Ethnic Populations
Current Pharmacogenomics The Synthesis of Risedronic Acid and Alendronate Applying Phosphorus Oxychloride and Phosphorous Acid in Methanesulfonic Acid
Letters in Drug Design & Discovery Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma
Current Radiopharmaceuticals Development and Applications of Optical Imaging Techniques in Cancer Diagnosis: Diffuse Optical Tomography and Microendoscopy
Current Medical Imaging Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Magnetic Resonance Imaging in the Encephalopathic Term Newborn
Current Pediatric Reviews Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Recent Patents Regarding Essential Oils and the Significance of their Constituents in Human Health and Treatment
Recent Patents on Anti-Infective Drug Discovery Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian Cancer
Current Medicinal Chemistry The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area
Current Topics in Medicinal Chemistry Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Improvement of Prediction of Mutation Positions in H5N1 Hemagglutinins of Influenza A Virus Using Neural Network with Distinguishing of Arginine, Leucine and Serine
Protein & Peptide Letters Assessing the Serum Levels of Ferritin and Selenium in three Important Infections of Childhood, Compared to a Control Group
Current Nutrition & Food Science Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy